WO1999052469A9 - Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger - Google Patents

Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger

Info

Publication number
WO1999052469A9
WO1999052469A9 PCT/US1999/007912 US9907912W WO9952469A9 WO 1999052469 A9 WO1999052469 A9 WO 1999052469A9 US 9907912 W US9907912 W US 9907912W WO 9952469 A9 WO9952469 A9 WO 9952469A9
Authority
WO
WIPO (PCT)
Prior art keywords
fumarate
poly
molecular weight
polydispersity index
average molecular
Prior art date
Application number
PCT/US1999/007912
Other languages
French (fr)
Other versions
WO1999052469A1 (en
Inventor
Susan J Peter
Laura J Suggs
Paul S Engel
Antonios G Mikos
Original Assignee
Univ Wm Marsh Rice
Susan J Peter
Laura J Suggs
Paul S Engel
Antonios G Mikos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wm Marsh Rice, Susan J Peter, Laura J Suggs, Paul S Engel, Antonios G Mikos filed Critical Univ Wm Marsh Rice
Priority to DE69924369T priority Critical patent/DE69924369D1/en
Priority to AT99915349T priority patent/ATE291444T1/en
Priority to JP2000543082A priority patent/JP2002539275A/en
Priority to EP99915349A priority patent/EP1079869B1/en
Priority to CA002327730A priority patent/CA2327730A1/en
Publication of WO1999052469A1 publication Critical patent/WO1999052469A1/en
Publication of WO1999052469A9 publication Critical patent/WO1999052469A9/en
Priority to US09/678,816 priority patent/US6355755B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/12Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/52Polycarboxylic acids or polyhydroxy compounds in which at least one of the two components contains aliphatic unsaturation
    • C08G63/56Polyesters derived from ester-forming derivatives of polycarboxylic acids or of polyhydroxy compounds other than from esters thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/0047Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L24/0073Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
    • A61L24/0084Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix containing fillers of phosphorus-containing inorganic compounds, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/046Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/18Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/12Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/52Polycarboxylic acids or polyhydroxy compounds in which at least one of the two components contains aliphatic unsaturation

Definitions

  • This invention relates to methods for the synthesis of high molecular weight forms of poly(propylene fumarate) having a relatively low polydispersity index. More particularly, the present invention provides methods for synthesizing poly(propylene fumarate) having molecular weights above 4,000 and polydispersity indices below 2, and more particularly below 1.8, wherein the high molecular weight poly(propylene fumarate) is synthesized in the presence of a proton scavenger.
  • BACKGROUND OF THE INVENTION It is often desired to replace or reconstruct all or a portion of a living bone, such as when a bone has been broken or has been resected as a result of a bone tumor.
  • the missing bone can be replaced with a mechanical device, such as a pin, plate or the like, or it can be replaced with an implant that is designed to more closely resemble the original bone itself.
  • these implants comprise biodegradable compounds or parts made from such compounds.
  • porous, biodegradable compounds that contain or are coated with an osteogenic substance. It is contemplated that bone tissue will grow back into the pores of the implant and will gradually replace the entire implant as the implant itself is gradually degraded in the in vivo environment.
  • implants regardless of whether they are biodegradable, should be biocompatible and non-toxic.
  • steps required for implantation of the implant eg. the application or generation of heat and the generation of chemical by-products
  • the techniques and time periods required for implantation should be suited to the surgical environment.
  • bone implants are typically formed from a substance that is initially malleable and then becomes hard after a reasonably short period of time. Because living bone tends to atrophy and degrade in the absence of compressive stress, however, it is important that the implant not become too hard. An implant whose compressive strength is too great (i.e. an implant that is too hard) will cause stress shielding of the surrounding bone. Stress shielding in turn causes the surrounding bone to weaken and may ultimately result in catastrophic failure. Hence, the suitability of a given substance for implantation as a bone replacement depends on its biocompatibility, set time, biodegradability and ultimate compressive strength. Certain polymers have been found to be suitable in this regard.
  • P(PF) Poly(propylene fumarate)
  • P(PF) is an unsaturated linear polyester that degrades in the presence of water into propylene glycol and fumaric acid, degradation products that are cleared from the human body by normal metabolic processes.
  • P(PF) is a known polymer, its routine, reproducible synthesis and the synthesis of high molecular weight forms and forms with low polydispersity indices have not previously been successfully accomplished.
  • Known methods for the synthesis of P(PF), for example by equilibrium polycondensation, utilize reactions that are difficult to control. These synthetic methods typically require extremely high heat, the presence of a catalyst, and/or long reaction times.
  • P(PF) fumarate double bonds in P(PF) are reactive and crosslink at low temperatures, making it valuable as an in situ polymerizable biomaterial.
  • An effective composite mixture incorporating P(PF), a crosslinking monomer (N-vinyl pyrrolidinone), a porogen (sodium chloride), and a particulate phase ( ⁇ -tricalcium phosphate) can be injected into skeletal defects of irregular shape or size.
  • the mechanical properties of the cured material can be tailored by altering the ratios of the porogen and particulate phase, as well as the monomer to polymer ratio.
  • the maximum molecular weight M w of the P(PF) polymer that has heretofore been reasonably achievable without encountering an unacceptably high polydispersity index is limited to less than 3,000.
  • P(PF) polymers have been produced having M w above 3,000, but because the degree of cross-linking varies greatly within the specimen, the polydispersity indices, (the ratio of weight average molecular weight to number average molecular weight), for these polymers are well above 2.0.
  • Premature crosslinking of the polymer often limits the linear size or molecular weight of the linear polymer that can be achieved. It is believed that this is in part due to the fact that some of the fumarate double bonds are reaction sites for the acid-catalyzed addition of various other groups.
  • the present invention provides a method for making high molecular weight linear poly(propylene fumarate) having a relatively low polydispersity index by utilizing a relatively pure intermediate.
  • fumaryl chloride and propylene glycol are reacted in the presence of potassium carbonate, which serves as a proton scavenger, to produce bis(propyl fumarate).
  • the reaction of fumaryl chloride and propylene glycol also produces HC1.
  • the potassium carbonate present in the reaction solution reacts with the HC1 to give water and CO 2 and prevents the acid from catalyzing reactions at the fumarate double bond.
  • a mole ratio of K 2 CO 3 to fumaryl chloride of between approximately 1.2:1 and 3:1 is used.
  • the bis(propyl fumarate) produced according to this technique can be transesterified using conventional processing steps to yield P(PF).
  • the P(PF) produced from bis(propyl fumarate) produced according to the present method has a higher molecular weight and is purer than P(PF) produced using previously known techniques.
  • Figure 1 is a labeled chemical structure of polypropylene fumarate
  • Figure 2 is a two-step reaction scheme for the formation of poly(propylene fumarate) from propylene glycol and fumaryl chloride;
  • Figure 3 is an FTIR spectra of poly(propylene fumarate) following transesterification and of the short chain oligomer prior to transesterification;
  • Figures 4A-C are a series of NMR spectra confu ⁇ ning the structure illustrated in
  • PI polydispersity indices
  • P(PF) is shown and various functional groups are labeled 1-6.
  • the structure depicted in Figure 1 is confirmed by the peaks labeled correspondingly 1-6 in Figures 4A-C, as described in detail below.
  • P(PF) n for which n equals at least 10 and more preferably at least 14 can be manufactured consistently and with a relatively high polydispersity index in a two-step process.
  • the first step includes acylation of propylene glycol with fumaryl chloride in the presence of a proton scavenger.
  • the acylation step releases 2HC1, which results in a lowering of the pH of the reaction solution.
  • potassium carbonate is preferably added in molar excess, to ensure that the acid catalysis of bonding across the double bonds is rni mized. This process produces a low molecular weight oligomer, bis ropyl fumarate), which can then be transesterified according to known techniques.
  • the formation of PPF is a two-step reaction process.
  • the first step involves forming a short chain oligomer from fumaryl chloride and propylene glycol in the presence of potassium carbonate. This is followed by a transesterification step to form the high molecular weight polymer, PPF.
  • the specifics of each reaction are described below.
  • Example 1 Materials Fumaryl chloride (Acros, Pittsburgh, PA) was purified by distillation at 159- 161°C. Propylene glycol was also obtained from Acros and used as received. Anhydrous potassium carbonate (Fisher, Pittsburgh, PA) was ground into a fine powder with a mortar and pestle. The solvents for polymer purification were purchased from Fisher as reagent grade and used as received.
  • Oligomer preparation Fumaryl chloride, propylene glycol, and potassium carbonate were measured out in a 1:3:1.5 molar ratio.
  • the propylene glycol was dissolved in chloroform (1:2 by volume) and placed in a 2 L-3 neck flask along with the powdered potassium carbonate. This mixture was stirred with an overhead mechanical stirrer to form a slurry.
  • Fumaryl chloride dissolved in chloroform (1:1 volume ratio) was added dropwise to the slurry.
  • the reaction mixture was maintained at room temperature (by altering the rate of the fumaryl chloride addition) under a nitrogen blanket. Additional chloroform was added as needed to facilitate stirring.
  • the mixture was transferred to 50 mL centrifuge tubes and spun down for 15 minutes at 4000 rpm until the potassium carbonate was completely removed. The supernatant was then added dropwise to petroleum ether to force the oligomer out of solution, .and the precipitate was rotary- evaporated to yield an amber-colored oil.
  • the oligomer was transferred to a 1 L-3 neck reaction vessel suspended in an oil bath.
  • the bath temperature was raised to 160°C and the system was evacuated to a pressure of 100-110 mm Hg.
  • Nitrogen was passed through a coil in the oil bath for preheating and subsequently bubbled into the bottom of the reaction vessel to facilitate mixing and maintain an inert environment.
  • Propylene glycol was liberated by the formation of each O-CO bond during the transesterification and was condensed as a byproduct. Samples for kinetic analysis of the molecular weight progression were removed each hour during the reaction. Upon termination of the transesterification, the vessel was pressurized to 1 arm and the product was allowed to cool.
  • F77R Fourier transform infrared spectra were obtained on a Nicolet 500 spectrometer (Madison, WI). Samples were placed on a zinc selenide attenuated total reflection crystal for analysis. A total of 32 scans was collected at a 4 cm “1 resolution. The peak at 2300 cm “1 is due to the presence of carbon dioxide in the sampling chamber.
  • N R Nuclear magnetic resonance spectra were obtained on a Bruker 500 MHz spectrometer (Switzerland). 'H, Distortionless Enhancement by Polarization Transfer-135 13 C (DEPT-135 !3 C), and 2D 'H- 13 C chemical shift correlation spectra of PPF were acquired using standard pulse programs.
  • GPC Gel permeation chromatography was used to determine polymer molecular weight distributions through the application of a differential refractometer detector (Waters, Model 410, Milford, MA).
  • a Phenogel guard column 50x7.8 mm, 5 ⁇ m, mixed bed, Phenomenex, Torrance, CA
  • a Phenogel column 300x7.8 mm, 5 ⁇ m, mixed bed, Phenomenex
  • Polystyrene standards were used to obtain a calibration curve for calculating the polymer molecular weights. Samples were analyzed for four transesterification reactions, each spanning a 16 hour time frame.
  • the peak assignments are based on calculated proton and carbon chemical shifts found from the tabulated values in Silverstein et al. 10
  • Acylation of propylene glycol to leave a primary alcohol resulted in a methylene peak (6) with signals at 'H 3.57-3.69 and i3 C 64.7 and a methine peak (5) with signals at ⁇ 5.0-5.12 and 13 C 72.4-73.1.
  • Acylation of propylene glycol to leave a secondary alcohol resulted in a methylene peak (3) with signals at ⁇ 4.03-4.17 and 13 C 69.8-70.1 and a methine peak (2) with signals at 'H 4.08-4.11 and 13 C 65.2.
  • the spectra of the short chain oligomer and the higher molecular weight polymer were investigated to confirm these peak assignments.
  • the secondary alcohol methylene (3) and primary alcohol methine (5) each produced two signals.
  • the signals within each pair were of approximately the same intensity in the oligomer spectrum.
  • one signal from each pair was more intense.
  • the weaker of the two signals was attributed to the polymer end groups, while the stronger signals were assigned to the interior CH and CH 2 of the polymer chain.
  • the stronger signals were more deshielded than the weaker ones because the interior species are located between two ester functionalities.
  • integrated 'H spectra gave a ratio of double bond hydrogens to methyl protons of 2:3, as expected from the backbone structure.
  • FIG. 4(a) shows the 2-D ⁇ - I3 C coupled NMR spectrum for ⁇ region 1.0-1.5 ppm and I3 C region 15.5-20 ppm. The number 1 corresponds to the methyl functionality labeled in Fig 1.
  • Figure 4(b) shows a 2-D ⁇ - 13 C coupled NMR spectrum for "H region 3.0-5.5 ppm and 13 C region 64-74 ppm.
  • the number 2 corresponds to the propyl methine and 3 corresponds to the propyl methylene of the secondary alcohol functionality labeled in Figure 1
  • 5 corresponds to the propyl methine
  • 6 corresponds to the propyl methylene of the primary alcohol functionality labeled in Figure 1.
  • the label PG-1 refers to methylene from the residual propylene glycol
  • the label PG-2 represents methine from the residual propylene glycol.
  • Figure 4(c) shows a 2-D "H- 13 C coupled NMR spectrum for 'H region 6.8-7.0 ppm and 13 C region 127-143 ppm.
  • the number 4 corresponds to the fumarate double bond atoms as labeled in Figure 1.
  • Peaks not attributable to P(PF) and due to residual propylene glycol are present at ⁇ 1.1 ppm and 13 C 18.8-19.0 ppm for the methyl groups, and at 'H 3.3-3.5 and 3.8-3.9 ppm and 13 C 67.6-68.2 and 68.2-68.6 ppm, respectively, for the methylene and methine groups.
  • the present invention provides an efficient and reproducible technique for synthesizing P(PF) having a molecular weight above 4,000 and a low polydispersity index.
  • This P(PF) is particularly well suited for use in bone cements.
  • a P(PF)-containing composition that is an effective bone cement is described in detail in co-pending Application Serial No. , filed concurrently herewith and entitled Bone Replacement Compound
  • the P(PF) can be incorporated into a paste, along with a monomer capable of addition polymerization an inorganic filler such as beta- tricalcium phosphate, sodium chloride or hydroxyapatite, a radical initiator such as benzoyl peroxide, azobisisobutyronitrile, or acetyl peroxide, and an accelerator such as N,N dimethyl toluidine.
  • a monomer capable of addition polymerization an inorganic filler such as beta- tricalcium phosphate, sodium chloride or hydroxyapatite, a radical initiator such as benzoyl peroxide, azobisisobutyronitrile, or acetyl peroxide, and an accelerator such as N,N dimethyl toluidine.
  • suitable monomer include vinyl pyrrolidone, acrylic acid, methyl methacrylate, styrene, methacrylic acid, or 2-hydroxy ethyl methacrylate, and copolymers thereof.
  • the monomers used are biodegradable, it is contemplated that non-biodegradable monomers such as methyl methacrylate will form only short polymer chains, which, upon degradation of the poly(propylene fumarate) backbone, in vivo, will be cleared from a patient's body by normal metabolic processes.
  • Various amounts of the specific ingredients may be combined to produce a useful product. For example, approximately equal amounts of the poly(propylene fumarate), monomer, and filler may be used. The amounts of each component may be varied according to the desired characteristics of the final composition, as known to one of skill in the art. Likewise, the amount of initiator and accelerator may be varied by one of skill in the art to produce a composite having desired physical characteristics.
  • the components are combined in a sterile field, and pass through a moldable putty stage prior to hardening.
  • a composite material having desired strength and modulus characteristics including that which approximates the physical characteristics of human trabecular bone, is produced.

Abstract

High molecular weight linear poly(propylene fumarate) having a relatively low polydispersity index by utilizing a relatively pure intermediate and a method for making same. Fumaryl chloride and propylene glycol are reacted in the presence of potassium carbonate. The potassium carbonate present in the reaction solution prevents the acid by-product from catalyzing reactions at the fumarate double bond. The bis(propyl fumarate) produced according to this technique can be transesterified using conventional processing steps to yield P(PF). The P(PF) produced from bis(propyl fumarate) produced according to the present method has a higher molecular weight and is purer than P(PF) produced using previously known techniques.

Description

SYNTHESIS OF POLYPROPYLENE FUMARATE)
BY ACYLATION OF PROPYLENE GLYCOL IN THE PRESENCE OF A PROTON SCAVENGER
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of provisional applications Serial No.
60/081,308, filed April 10, 1998 and entitled Synthesis of Poly(Proplyene Fumarate) by
Acylation ofPropylene Glycol in the Presence of a Proton Scavenger; Serial No. 60/082,182, filed April 16, 1998 and entitled In Vivo Degradation of a Poly(Propylene Fumarate)/ -
Tricalcium Phosphate Injectable Composite Scaffold; and Serial No. 60/018,405, filed April
10, 1998 and entitled Crosslinking Characteristics of an Injectable Poly(Propylene
Fumarate)/ Tricalcium Phosphate Past and Mechanical Properties of the Crosslinked
Composite for Use as a Biodegradable Bone Cement. STATEMENTREGARDINGFEDERALLY SPONSORED
RESEARCHORDEVELOPMENT
This work was funded by the National Institutes of Health (R01-AR44381) (AGM), the National Science Foundation (PSE), and National Institutes of Health Biotechnology Training Grant 5T32GM08362.
TECHNICAL FIELD OF THE INVENTION This invention relates to methods for the synthesis of high molecular weight forms of poly(propylene fumarate) having a relatively low polydispersity index. More particularly, the present invention provides methods for synthesizing poly(propylene fumarate) having molecular weights above 4,000 and polydispersity indices below 2, and more particularly below 1.8, wherein the high molecular weight poly(propylene fumarate) is synthesized in the presence of a proton scavenger.
BACKGROUND OF THE INVENTION It is often desired to replace or reconstruct all or a portion of a living bone, such as when a bone has been broken or has been resected as a result of a bone tumor. In these instances, the missing bone can be replaced with a mechanical device, such as a pin, plate or the like, or it can be replaced with an implant that is designed to more closely resemble the original bone itself. Often these implants comprise biodegradable compounds or parts made from such compounds. For example, it is known to provide porous, biodegradable compounds that contain or are coated with an osteogenic substance. It is contemplated that bone tissue will grow back into the pores of the implant and will gradually replace the entire implant as the implant itself is gradually degraded in the in vivo environment.
For obvious reasons, implants, regardless of whether they are biodegradable, should be biocompatible and non-toxic. Furthermore, the steps required for implantation of the implant (eg. the application or generation of heat and the generation of chemical by-products) should also be biocompatible and non-toxic. Also, the techniques and time periods required for implantation should be suited to the surgical environment.
Under current practices, bone implants are typically formed from a substance that is initially malleable and then becomes hard after a reasonably short period of time. Because living bone tends to atrophy and degrade in the absence of compressive stress, however, it is important that the implant not become too hard. An implant whose compressive strength is too great (i.e. an implant that is too hard) will cause stress shielding of the surrounding bone. Stress shielding in turn causes the surrounding bone to weaken and may ultimately result in catastrophic failure. Hence, the suitability of a given substance for implantation as a bone replacement depends on its biocompatibility, set time, biodegradability and ultimate compressive strength. Certain polymers have been found to be suitable in this regard.
Poly(propylene fumarate) (hereinafter "P(PF)") is one such substance. P(PF) is an unsaturated linear polyester that degrades in the presence of water into propylene glycol and fumaric acid, degradation products that are cleared from the human body by normal metabolic processes. Although P(PF) is a known polymer, its routine, reproducible synthesis and the synthesis of high molecular weight forms and forms with low polydispersity indices have not previously been successfully accomplished. Known methods for the synthesis of P(PF), for example by equilibrium polycondensation, utilize reactions that are difficult to control. These synthetic methods typically require extremely high heat, the presence of a catalyst, and/or long reaction times.
Nevertheless, the fumarate double bonds in P(PF) are reactive and crosslink at low temperatures, making it valuable as an in situ polymerizable biomaterial. An effective composite mixture incorporating P(PF), a crosslinking monomer (N-vinyl pyrrolidinone), a porogen (sodium chloride), and a particulate phase (β-tricalcium phosphate) can be injected into skeletal defects of irregular shape or size. As is known in the art, the mechanical properties of the cured material can be tailored by altering the ratios of the porogen and particulate phase, as well as the monomer to polymer ratio.
The maximum molecular weight Mw of the P(PF) polymer that has heretofore been reasonably achievable without encountering an unacceptably high polydispersity index is limited to less than 3,000. P(PF) polymers have been produced having Mw above 3,000, but because the degree of cross-linking varies greatly within the specimen, the polydispersity indices, (the ratio of weight average molecular weight to number average molecular weight), for these polymers are well above 2.0. Premature crosslinking of the polymer often limits the linear size or molecular weight of the linear polymer that can be achieved. It is believed that this is in part due to the fact that some of the fumarate double bonds are reaction sites for the acid-catalyzed addition of various other groups. The presence of these groups and the corresponding elimination of the double bond reduces the degree of unsaturation and thus limits molecular weight. Early attempts to mitigate this effect and increase the weight average molecular weight entailed the use of an amine to neutralize the acid, but results of this reaction were undesirable. Other early attempts included the use of buffers, and several other materials also proved ineffective.
Hence, it is highly desirable to provide an efficient, controlled synthetic reaction whereby high molecular weight linear poly(propylene fumarate) having a relatively low polydispersity index can reproducibly synthesized without regardless of whether .an acid catalyst is used.
BRIEF SUMMARY OF THE INVENTION The present invention provides a method for making high molecular weight linear poly(propylene fumarate) having a relatively low polydispersity index by utilizing a relatively pure intermediate. According to the present invention, fumaryl chloride and propylene glycol are reacted in the presence of potassium carbonate, which serves as a proton scavenger, to produce bis(propyl fumarate). The reaction of fumaryl chloride and propylene glycol also produces HC1. The potassium carbonate present in the reaction solution reacts with the HC1 to give water and CO2 and prevents the acid from catalyzing reactions at the fumarate double bond. According to a preferred embodiment, a mole ratio of K2CO3 to fumaryl chloride of between approximately 1.2:1 and 3:1 is used. The bis(propyl fumarate) produced according to this technique can be transesterified using conventional processing steps to yield P(PF). The P(PF) produced from bis(propyl fumarate) produced according to the present method has a higher molecular weight and is purer than P(PF) produced using previously known techniques.
BRIEF DESCRIPTION OF THE DRA WTNGS
For an introduction to the detailed description of the preferred embodiments of the invention, reference will now be made to the accompanying Figures, wherein:
Figure 1 is a labeled chemical structure of polypropylene fumarate);
Figure 2 is a two-step reaction scheme for the formation of poly(propylene fumarate) from propylene glycol and fumaryl chloride;
Figure 3 is an FTIR spectra of poly(propylene fumarate) following transesterification and of the short chain oligomer prior to transesterification; and
Figures 4A-C are a series of NMR spectra confuτning the structure illustrated in
Figure 1.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS It has been discovered that the P(PF)s formed according to the preferred embodiment have greater molecular weights than those produced by previously known reaction methods without requiring the use of a catalyst. Equally importantly, the preferred method yields P(PF)s having polydispersity indices, or PI (PI = Mw / M„ where Mw is the weight average molecular weight and M„ is the number average molecular weight), less than 2 and more preferably approximately 1. Referring initially to Figure 1, the chemical structure for the desired reaction product
P(PF) is shown and various functional groups are labeled 1-6. The structure depicted in Figure 1 is confirmed by the peaks labeled correspondingly 1-6 in Figures 4A-C, as described in detail below. According to the present invention, P(PF)n for which n equals at least 10 and more preferably at least 14, can be manufactured consistently and with a relatively high polydispersity index in a two-step process. The first step includes acylation of propylene glycol with fumaryl chloride in the presence of a proton scavenger. As generally disclosed in U.S. Patent 5,733,951, which is incorporated herein in its entirety, the acylation step releases 2HC1, which results in a lowering of the pH of the reaction solution. In prior art processes, the presence of the acid allowed the acid-catalyzed addition of various other groups, such as excess propylene glycol, at the fumarate double bond. These undesired side reactions reduced the purity of the desired bis(propyl fumarate) intermediate and thus increased the polydispersity index and reduced the maximum molecular weight of the ultimate P(PF) product that can be obtained.
It has been discovered that the addition of potassium carbonate to the reaction solution effectively neutralizes the acid and prevents premature loss of the fumarate double bond. The potassium carbonate is preferably added in molar excess, to ensure that the acid catalysis of bonding across the double bonds is rni mized. This process produces a low molecular weight oligomer, bis ropyl fumarate), which can then be transesterified according to known techniques.
As shown in Figure 2, the formation of PPF is a two-step reaction process. The first step involves forming a short chain oligomer from fumaryl chloride and propylene glycol in the presence of potassium carbonate. This is followed by a transesterification step to form the high molecular weight polymer, PPF. The specifics of each reaction are described below. Example 1 Materials Fumaryl chloride (Acros, Pittsburgh, PA) was purified by distillation at 159- 161°C. Propylene glycol was also obtained from Acros and used as received. Anhydrous potassium carbonate (Fisher, Pittsburgh, PA) was ground into a fine powder with a mortar and pestle. The solvents for polymer purification were purchased from Fisher as reagent grade and used as received. Oligomer preparation. Fumaryl chloride, propylene glycol, and potassium carbonate were measured out in a 1:3:1.5 molar ratio. The propylene glycol was dissolved in chloroform (1:2 by volume) and placed in a 2 L-3 neck flask along with the powdered potassium carbonate. This mixture was stirred with an overhead mechanical stirrer to form a slurry. Fumaryl chloride dissolved in chloroform (1:1 volume ratio) was added dropwise to the slurry. The reaction mixture was maintained at room temperature (by altering the rate of the fumaryl chloride addition) under a nitrogen blanket. Additional chloroform was added as needed to facilitate stirring. Upon completion of the fumaryl chloride addition, the mixture was transferred to 50 mL centrifuge tubes and spun down for 15 minutes at 4000 rpm until the potassium carbonate was completely removed. The supernatant was then added dropwise to petroleum ether to force the oligomer out of solution, .and the precipitate was rotary- evaporated to yield an amber-colored oil.
Transesterification. The oligomer was transferred to a 1 L-3 neck reaction vessel suspended in an oil bath. The bath temperature was raised to 160°C and the system was evacuated to a pressure of 100-110 mm Hg. Nitrogen was passed through a coil in the oil bath for preheating and subsequently bubbled into the bottom of the reaction vessel to facilitate mixing and maintain an inert environment. Propylene glycol was liberated by the formation of each O-CO bond during the transesterification and was condensed as a byproduct. Samples for kinetic analysis of the molecular weight progression were removed each hour during the reaction. Upon termination of the transesterification, the vessel was pressurized to 1 arm and the product was allowed to cool. This product was dissolved in chloroform and precipitated through dropwise addition of the mixture to petroleum ether with stirring. The precipitate was rotary-evaporated for 2 hours. The final product, PPF, was a much darker color and of a greater viscosity when compared to PPF synthesized in the absence of potassium carbonate. Moreover, the transesterification reaction no longer catalytic antimony trioxide, an undesirable compound for in vivo applications. For the polymer characterization described below, PPF prepared from a 16 hour transesterification with a number average molecular weight of approximately 5000 Da was used. Polymer Characterization.
F77R Fourier transform infrared spectra were obtained on a Nicolet 500 spectrometer (Madison, WI). Samples were placed on a zinc selenide attenuated total reflection crystal for analysis. A total of 32 scans was collected at a 4 cm"1 resolution. The peak at 2300 cm"1 is due to the presence of carbon dioxide in the sampling chamber. N R Nuclear magnetic resonance spectra were obtained on a Bruker 500 MHz spectrometer (Switzerland). 'H, Distortionless Enhancement by Polarization Transfer-135 13C (DEPT-135 !3C), and 2D 'H-13C chemical shift correlation spectra of PPF were acquired using standard pulse programs. MS Mass spectral data of the oligomer and high molecular weight polymer were obtained in fast-atom bombardment (FAB) mode on a Finnigan MAT 95 spectrometer (New York, NY) using a Cs ion gun. Nitrobenzyl alcohol was used as a matrix.
GPC Gel permeation chromatography was used to determine polymer molecular weight distributions through the application of a differential refractometer detector (Waters, Model 410, Milford, MA). A Phenogel guard column (50x7.8 mm, 5 μm, mixed bed, Phenomenex, Torrance, CA) and a Phenogel column (300x7.8 mm, 5μm, mixed bed, Phenomenex) were used to elute the samples at 1 mL/min chloroform flow rate. Polystyrene standards were used to obtain a calibration curve for calculating the polymer molecular weights. Samples were analyzed for four transesterification reactions, each spanning a 16 hour time frame.
Results
F77R Carbonyl stretching at 1714 cm"1, C=C stretching at 1640 cm'1, and methylene scissoring and asymmetric bending at 1457 cm"1 were all evident in the FTTR spectra of the oligomer and final polymer (Figure 3). C-O stretching at 1266 cm"1, methyl symmetric bending at 1382 cm"1, and the C-H bend of the double bond at 983 cm'1 were also present in both spectra. The oligomer had a more intense OH stretch at 3340 cm"1 than the higher molecular weight polymer due to the greater number of hydroxyl end groups in the short chain oligomer. The relative intensity of the hydroxyl peak decreased with increasing molecular weight of the samples taken throughout the transesterification. No major differences were identified in the FTTR spectra of the PPF formed through the new reaction pathway as opposed to the previous method.
NMR Through the combination of proton, carbon, and two-dimensional proton-carbon chemical shift correlation spectra, the PPF chemical structure represented in Figure 1 was verified. Contour positions for all pertinent functional groups represented in this structure are given in Table 1 and shown in Figures 4(a)-(c).
Table 1. Identification of Functional Group Contours From the 2-d Proton-Carbon Correlation NMR Spectra.
Figure imgf000009_0001
The peak assignments are based on calculated proton and carbon chemical shifts found from the tabulated values in Silverstein et al.10 Acylation of propylene glycol to leave a primary alcohol resulted in a methylene peak (6) with signals at 'H 3.57-3.69 and i3C 64.7 and a methine peak (5) with signals at Η 5.0-5.12 and 13C 72.4-73.1. Acylation of propylene glycol to leave a secondary alcohol resulted in a methylene peak (3) with signals at Η 4.03-4.17 and 13C 69.8-70.1 and a methine peak (2) with signals at 'H 4.08-4.11 and 13C 65.2. The spectra of the short chain oligomer and the higher molecular weight polymer were investigated to confirm these peak assignments. The secondary alcohol methylene (3) and primary alcohol methine (5) each produced two signals. The signals within each pair were of approximately the same intensity in the oligomer spectrum. However, in the high molecular weight polymer spectrum, one signal from each pair was more intense. The weaker of the two signals was attributed to the polymer end groups, while the stronger signals were assigned to the interior CH and CH2 of the polymer chain. The stronger signals were more deshielded than the weaker ones because the interior species are located between two ester functionalities. Furthermore, integrated 'H spectra gave a ratio of double bond hydrogens to methyl protons of 2:3, as expected from the backbone structure. The integrated spectra of P(PF) produced by the previous method showed a ratio of 1 :3, verifying loss of polymer unsaturation. Figure 4(a) shows the 2-D Η-I3C coupled NMR spectrum for Η region 1.0-1.5 ppm and I3C region 15.5-20 ppm. The number 1 corresponds to the methyl functionality labeled in Fig 1. Figure 4(b) shows a 2-D Η-13C coupled NMR spectrum for "H region 3.0-5.5 ppm and 13C region 64-74 ppm. The number 2 corresponds to the propyl methine and 3 corresponds to the propyl methylene of the secondary alcohol functionality labeled in Figure 1, and 5 corresponds to the propyl methine and 6 corresponds to the propyl methylene of the primary alcohol functionality labeled in Figure 1. The label PG-1 refers to methylene from the residual propylene glycol, and the label PG-2 represents methine from the residual propylene glycol. Figure 4(c) shows a 2-D "H-13C coupled NMR spectrum for 'H region 6.8-7.0 ppm and 13C region 127-143 ppm. The number 4 corresponds to the fumarate double bond atoms as labeled in Figure 1.
Peaks not attributable to P(PF) and due to residual propylene glycol are present at Η 1.1 ppm and 13C 18.8-19.0 ppm for the methyl groups, and at 'H 3.3-3.5 and 3.8-3.9 ppm and 13C 67.6-68.2 and 68.2-68.6 ppm, respectively, for the methylene and methine groups.
Major byproducts were identified in the NMR spectra of P(PF) produced by the previous synthetic method. Propylene glycol addition across the double bond led to peaks at 46.5 and 71 ppm, while HC1 addition produced additional methylene 'H signals at 2.8-3.3 ppm and 13C signals at 39-40 ppm and methine Η signals at 4.6-4.8 ppm and 13C signals at 51-52 ppm. Since no evidence of either of these side products was seen in any of the NMR spectra collected in the present study, the addition of K2CO3 represents a great improvement over the previous synthetic method.
Kinetic studies of the transesterification showed that the molecular weight of a P(PF) reached a final M. of 4900 (±700) and Mw of 9100 (±1300) after 16 hours, while the polydispersity index remained below 1.8 throughout the reaction. Thus the P(PF) synthesized by the new method is of higher molecular weight and greater purity than previously prepared material having the same formula. According to two dimensional NMR, the backbone structure of this polymer was as expected and contained no byproducts formed by acid catalyzed addition across the fumarate double bond. It is expected that the present technique will have applicability to P(PF) formation reactions regardless of whether those reactions include the use of a catalyst.
In sum, the present invention provides an efficient and reproducible technique for synthesizing P(PF) having a molecular weight above 4,000 and a low polydispersity index. This P(PF) is particularly well suited for use in bone cements. A P(PF)-containing composition that is an effective bone cement is described in detail in co-pending Application Serial No. , filed concurrently herewith and entitled Bone Replacement Compound
Comprising Poly (Polypropylene Fumarate), which is incorporated by reference herein in its entirety. While a preferred embodiment has been disclosed and described, it will be understood that certain modifications could be made without departing from the scope of the present invention. For example, the potassium carbonate that serves as an acid neutralizer in the preferred embodiment could be replaced with any suitable proton scavenger, such as but not limited to similar salts, including other alkaline earth and alkali metal carbonates. As discussed above, the P(PF) made according to the present invention is suitable for use in a replacement compound for living bone. The P(PF) can be incorporated into a paste, along with a monomer capable of addition polymerization an inorganic filler such as beta- tricalcium phosphate, sodium chloride or hydroxyapatite, a radical initiator such as benzoyl peroxide, azobisisobutyronitrile, or acetyl peroxide, and an accelerator such as N,N dimethyl toluidine. Examples of suitable monomer include vinyl pyrrolidone, acrylic acid, methyl methacrylate, styrene, methacrylic acid, or 2-hydroxy ethyl methacrylate, and copolymers thereof. While it is preferred that the monomers used are biodegradable, it is contemplated that non-biodegradable monomers such as methyl methacrylate will form only short polymer chains, which, upon degradation of the poly(propylene fumarate) backbone, in vivo, will be cleared from a patient's body by normal metabolic processes. Various amounts of the specific ingredients may be combined to produce a useful product. For example, approximately equal amounts of the poly(propylene fumarate), monomer, and filler may be used. The amounts of each component may be varied according to the desired characteristics of the final composition, as known to one of skill in the art. Likewise, the amount of initiator and accelerator may be varied by one of skill in the art to produce a composite having desired physical characteristics. Preferably, the components are combined in a sterile field, and pass through a moldable putty stage prior to hardening. In addition, by varying the molecular weight of the poly(propylene fumarate) a composite material having desired strength and modulus characteristics, including that which approximates the physical characteristics of human trabecular bone, is produced.

Claims

CLAIMSWhat is claimed is:
1. Poly(polypropylene fumarate) having a weight average molecular weight above 5,000 and a polydispersity index below 2.0.
2. Poly(polypropylene fumarate) having a weight average molecular weight above 9,000 and a polydispersity index below 2.0.
3. A method for synthesizing poly(polypropylene fumarate), comprising:
(a) reacting fumaryl chloride to form bis(hydroxypropyl fumarate); and
(b) transesterifying the bis(hydroxypropyl fumarate); wherein step (a) is carried out in the presence of a proton scavenger.
4. The method of claim 3 wherein the proton scavenger is selected from the group comprising amines, buffers and carbonate salts.
5. The method of claim 3 wherein the proton scavenger is selected from the group comprising alkali metal carbonates and alkaline-earth metal carbonates.
6. The method of claim 3 wherein the proton scavenger is potassium carbonate.
7. The method of claim 3 wherein step (b) produces poly(polypropylene fumarate) having a weight average molecular weight above 5,000 and a polydispersity index below 2.0.
8. The method of claim 3 wherein step (b) produces poly(polypropylene fumarate) having a weight average molecular weight above 9,000 and a polydispersity index below 2.0.
9. A composition suitable for use in orthopedic applications, comprising: poly(propylene fumarate); a monomer capable of addition polymerization; an inorganic filler; and a radical initiator; and wherein said poly(propylene fumarate) has a weight average molecular weight above 5,000 and a polydispersity index below 2.0.
10. The composition according to claim 9 wherein said monomer is selected from the group consisting of vinyl pyrrolidone, acrylic acid, methyl methacrylate, styrene, methacryhc acid, 2-hydroxy ethyl methacrylate, and copolymers thereof.
11. The composition according to claim 9 wherein said inorganic filler is selected from the group consisting of beta-tricalcium phosphate, sodium chloride, hydroxyapatite and combinations thereof.
12. The composition according to claim 9 wherein said radical initiator is selected from the group consisting of such as benzoyl peroxide, azobisisobutyronitrile, and acetyl peroxide.
13. The composition according to claim 9 wherein said poly(propylene fumarate) has a weight average molecular weight above 9,000 and a polydispersity index below 2.0.
14. The composition according to claim 13 wherein said composition includes an amount of cross linking agent between about 0.25 ml per gram of P(PF) and about 0.5 ml per gram ofP(PF).
15. The composition according to claim 13 wherein said composition includes an amount of initiator between about 0.001 grams per gram of P(PF) and about 0.005 grams per gram of P(PF).
16. The composition according to claim 13, further including an accelerator.
17. A method for synthesizing poly(polypropylene fumarate), comprising:
(a) reacting fumaryl chloride to form bis(hydroxypropyl fumarate);
(b) transesterifying the bis(hydroxypropyl fumarate); and (c) substantially maintaining the unsaturation of the fumarate.
18. The method of claim 16, including the step of carrying out step (a) in the presence of a proton scavenger.
19. The method of claim 17 wherein the proton scavenger is selected from the group comprising alkali metal carbonates and alkaline-earth metal carbonates.
20. The method of claim 18 wherein the proton scavenger is potassium carbonate.
21. The method of claim 16 wherein step (b) produces poly(polypropylene fumarate) having a weight average molecular weight above 5,000 and a polydispersity index below 2.0.
22. The method of claim 16 wherein step (b) produces poly(polypropylene fumarate) having a weight average molecular weight above 9,000 and a polydispersity index below 2.0.
PCT/US1999/007912 1998-04-10 1999-04-09 Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger WO1999052469A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE69924369T DE69924369D1 (en) 1998-04-10 1999-04-09 SYNTHESIS OF POLY (PROPYLENE FUMARATE) BY ACETYLATION OF PROPYLENE GLYCOL IN THE PRESENCE OF A PROTONATE FENDER
AT99915349T ATE291444T1 (en) 1998-04-10 1999-04-09 SYNTHESIS OF POLY(PROPYLENE NFUMARATE) BY ACETYLATION OF PROPYLENE GLYCOL IN THE PRESENCE OF A PROTON CAPTURER
JP2000543082A JP2002539275A (en) 1998-04-10 1999-04-09 Synthesis of poly (propylene fumarate) by acylation of propylene glycol in the presence of proton scavenger
EP99915349A EP1079869B1 (en) 1998-04-10 1999-04-09 Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger
CA002327730A CA2327730A1 (en) 1998-04-10 1999-04-09 Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger
US09/678,816 US6355755B1 (en) 1998-04-10 2000-10-04 Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8140598P 1998-04-10 1998-04-10
US8130898P 1998-04-10 1998-04-10
US8218298P 1998-04-16 1998-04-16
US60/081,308 1998-04-16
US60/081,405 1998-04-16
US60/082,182 1998-04-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/678,816 Continuation US6355755B1 (en) 1998-04-10 2000-10-04 Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger

Publications (2)

Publication Number Publication Date
WO1999052469A1 WO1999052469A1 (en) 1999-10-21
WO1999052469A9 true WO1999052469A9 (en) 2000-03-23

Family

ID=27373944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/007912 WO1999052469A1 (en) 1998-04-10 1999-04-09 Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger

Country Status (7)

Country Link
US (2) US6124373A (en)
EP (1) EP1079869B1 (en)
JP (1) JP2002539275A (en)
AT (1) ATE291444T1 (en)
CA (1) CA2327730A1 (en)
DE (1) DE69924369D1 (en)
WO (1) WO1999052469A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486232B1 (en) * 1997-04-18 2002-11-26 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for internal fixation devices and bone cements
WO1999052469A1 (en) 1998-04-10 1999-10-21 Wm. Marsh Rice University Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger
WO2000062630A1 (en) * 1999-04-16 2000-10-26 Wm. Marsh Rice University Functionalized poly(propylene fumarate) and poly(propylene fumarate-co-ethylene glycol)
US6884778B2 (en) * 2000-04-14 2005-04-26 William Marsh Rice University Biocompatible macromers
DE10032220A1 (en) * 2000-07-03 2002-01-24 Sanatis Gmbh Magnesium ammonium phosphate cements, their manufacture and use
US6849223B2 (en) * 2001-04-19 2005-02-01 Case Western Reserve University Fabrication of a polymeric prosthetic implant
JP2004536909A (en) * 2001-06-28 2004-12-09 ダブリューエム・マーシュ・ライス・ユニバーシティー Photocrosslinking of diethyl fumarate / poly (propylene fumarate) biomaterial
US7629388B2 (en) 2001-11-20 2009-12-08 William Marsh Rice University Synthesis and characterization of biodegradable cationic poly(propylene fumarate-co-ethylene glycol) copolymer hydrogels modified with agmatine for enhanced cell adhesion
EP1499267A4 (en) * 2002-02-05 2008-10-29 Depuy Mitek Inc Bioresorbable osteoconductive compositions for bone regeneration
US6884432B2 (en) * 2002-04-25 2005-04-26 Mayo Foundation For Medical Education And Research Blend, cross-linkable poly(propylene fumarate) for immobilization and controlled drug delivery
US7273523B2 (en) 2002-06-07 2007-09-25 Kyphon Inc. Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof
US20070065652A1 (en) * 2003-03-13 2007-03-22 Willaim Marsh Rice University Composite injectable and pre-fabricated bone replacement material and method for the production of such bone replacement material
WO2004080357A1 (en) 2003-03-14 2004-09-23 Ferreyro Irigoyen Roque Humber Hydraulic device for the injection of bone cement in percutaneous vertebroplasty
US8066713B2 (en) 2003-03-31 2011-11-29 Depuy Spine, Inc. Remotely-activated vertebroplasty injection device
US8415407B2 (en) 2004-03-21 2013-04-09 Depuy Spine, Inc. Methods, materials, and apparatus for treating bone and other tissue
CA2528150A1 (en) * 2003-07-01 2005-01-20 Mayo Foundation For Medical Education And Research Self-crosslinkable poly(caprolactone fumarate)
US7252686B2 (en) * 2003-08-13 2007-08-07 Boston Scientific Scimed Methods for reducing bone compression fractures using wedges
US8579908B2 (en) 2003-09-26 2013-11-12 DePuy Synthes Products, LLC. Device for delivering viscous material
US20060018949A1 (en) * 2004-04-07 2006-01-26 Bausch & Lomb Incorporated Injectable biodegradable drug delivery system
ES2396133T3 (en) 2004-04-27 2013-02-19 Kyphon SÀRl Bone replacement compositions and method of use
CA2575699C (en) 2004-07-30 2014-07-08 Disc-O-Tech Medical Technologies Ltd. Methods, materials and apparatus for treating bone and other tissue
AU2005304567B2 (en) 2004-11-12 2011-10-27 Mayo Foundation For Medical Education And Research Photocrosslinkable poly(caprolactone fumarate)
ATE540984T1 (en) * 2004-11-18 2012-01-15 Mayo Foundation BLOCK COPOLYMERS FROM POLYCAPROLACTONE AND POLY (PROPYLENE FUMARATE)
CA2606396A1 (en) * 2005-04-29 2006-11-09 Mayo Foundation For Medical Education And Research Hydrophilic/hydrophobic polymer networks based on poly(caprolactone fumarate), poly(ethylene glycol fumarate), and copolymers thereof
US9381024B2 (en) 2005-07-31 2016-07-05 DePuy Synthes Products, Inc. Marked tools
US9918767B2 (en) 2005-08-01 2018-03-20 DePuy Synthes Products, Inc. Temperature control system
US7651701B2 (en) * 2005-08-29 2010-01-26 Sanatis Gmbh Bone cement composition and method of making the same
US8360629B2 (en) 2005-11-22 2013-01-29 Depuy Spine, Inc. Mixing apparatus having central and planetary mixing elements
US7754005B2 (en) * 2006-05-02 2010-07-13 Kyphon Sarl Bone cement compositions comprising an indicator agent and related methods thereof
US7507286B2 (en) * 2006-06-08 2009-03-24 Sanatis Gmbh Self-foaming cement for void filling and/or delivery systems
WO2008001385A2 (en) * 2006-06-29 2008-01-03 Depuy Spine, Inc. Integrated bone biopsy and therapy apparatus
WO2008032322A2 (en) 2006-09-14 2008-03-20 Depuy Spine, Inc. Bone cement and methods of use thereof
US20080075788A1 (en) * 2006-09-21 2008-03-27 Samuel Lee Diammonium phosphate and other ammonium salts and their use in preventing clotting
CA2747850C (en) * 2006-10-19 2013-05-14 Depuy Spine, Inc. Fluid delivery system
WO2008073190A2 (en) * 2006-11-03 2008-06-19 Kyphon Sarl Materials and methods and systems for delivering localized medical treatments
ATE551967T1 (en) * 2007-07-30 2012-04-15 Purzer Pharmaceutical Co Ltd BIODEGRADABLE BONE CEMENT AND PRODUCTION PROCESS THEREOF
US20090286907A1 (en) * 2008-01-23 2009-11-19 Beltz Mark W Fumaric Acid/Diol Polyesters and Their Manufacture and Use
US7968616B2 (en) * 2008-04-22 2011-06-28 Kyphon Sarl Bone cement composition and method
EP2590605A1 (en) 2010-07-09 2013-05-15 Board of Regents of the University of Texas System Biodegradable scaffolds
JP6027533B2 (en) 2010-08-20 2016-11-16 ケース ウェスタン リザーブ ユニバーシティCase Western Reserve University Additional manufacturing of implants by continuous digital light processing
US11865785B2 (en) * 2010-08-20 2024-01-09 H. David Dean Continuous digital light processing additive manufacturing of implants
SG11201609348PA (en) 2014-05-05 2016-12-29 Sealantis Ltd Biological adhesives and sealants and methods of using the same
WO2016081587A1 (en) * 2014-11-18 2016-05-26 The University Of Akron Well-defined degradable poly(propylene fumarate) polymers and scalable methods for the synthesis thereof
JP2020506990A (en) 2017-02-02 2020-03-05 アクロン大学 Functionalized poly (propylene fumarate) polymer prepared by ring-opening polymerization using magnesium catalyst
GB2594243A (en) * 2020-04-15 2021-10-27 Arterius Ltd A bone cement
IL299833A (en) * 2020-07-15 2023-03-01 Univ Akron Synthesis of poly (propylene maleate-co-succinate) by the time-dependent reduction of poly (propylene maleate) double bonds mediated by zinc and acetic acid

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3701748A (en) 1966-07-20 1972-10-31 Rohm & Haas Unsaturated polyester resinous compositions
GB1225803A (en) * 1967-06-02 1971-03-24
US5286763A (en) * 1983-03-22 1994-02-15 Massachusetts Institute Of Technology Bioerodible polymers for drug delivery in bone
US4722948A (en) * 1984-03-16 1988-02-02 Dynatech Corporation Bone replacement and repair putty material from unsaturated polyester resin and vinyl pyrrolidone
US5989579A (en) 1986-10-02 1999-11-23 Escalon Medical Corp. Ocular insert with anchoring protrusions
US4843112A (en) * 1987-03-12 1989-06-27 The Beth Israel Hospital Association Bioerodable implant composition
US4888413A (en) 1988-01-11 1989-12-19 Domb Abraham J Poly(propylene glycol fumarate) compositions for biomedical applications
AU639645B2 (en) 1989-10-10 1993-07-29 Wm. Wrigley Jr. Company Gradual release structures made from fiber spinning techniques
FR2661682B1 (en) 1990-05-04 1993-12-10 Norsolor NEW RESINOUS COMPOSITIONS BASED ON UNSATURATED POLYESTER RESINS AND NEW ANTI-SHRINKAGE ADDITIVES.
CA2117588C (en) 1992-02-28 1998-08-25 Jeffrey A. Hubbell Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5733951A (en) * 1994-04-28 1998-03-31 Yaszemski; Michael J. Poly(propylene fumarate)
US5527864A (en) * 1995-08-08 1996-06-18 Suggs; Laura J. Poly(propylene fumarate-co-ethylene oxide)
US5946457A (en) 1995-12-25 1999-08-31 Sharp Kabushiki Kaisha Image forming system having transfer device for communicating between image forming apparatus and image processing apparatus
US5998362A (en) 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6071982A (en) 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
US5854382A (en) 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
WO1999052469A1 (en) 1998-04-10 1999-10-21 Wm. Marsh Rice University Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger

Also Published As

Publication number Publication date
US6355755B1 (en) 2002-03-12
DE69924369D1 (en) 2005-04-28
EP1079869A4 (en) 2002-08-07
EP1079869A1 (en) 2001-03-07
WO1999052469A1 (en) 1999-10-21
ATE291444T1 (en) 2005-04-15
CA2327730A1 (en) 1999-10-21
US6124373A (en) 2000-09-26
EP1079869B1 (en) 2005-03-23
JP2002539275A (en) 2002-11-19

Similar Documents

Publication Publication Date Title
EP1079869B1 (en) Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger
Kharas et al. Synthesis and characterization of fumarate‐based polyesters for use in bioresorbable bone cement composites
KR100696407B1 (en) Biodegradable polypropylene fumarate networks cross linked with polypropylene fumarate-diacrylate macromers
JP3481762B2 (en) Poly (alkylene diglycolate) s, copolymers, blends, their production methods and medical devices using them
US10844158B2 (en) Chain extenders
JP3161729B2 (en) Method for producing medically applicable article from copolymer of lactide and ε-caprolactone
EP1267953B1 (en) Compositions of crosslinkable prepolymers for biodegradable implants
JP2986509B2 (en) Modified polyester resin composition, method for producing the same, and use thereof
US5688900A (en) Absorbable polyalkylene diglycolates
JP5527968B2 (en) Hydrophilic / hydrophobic polymer networks based on poly (caprolactone fumarate), poly (ethylene glycol fumarate) and copolymers thereof
US20070117959A1 (en) Novel polyesters
EP0617712B1 (en) Copolymer of lactone and carbonate and process for the preparation of such a copolymer
US6602963B2 (en) Polyesters containing (meth)acrylate end groups
Peter et al. Poly (propylene fumarate)
EP0882085A1 (en) Biodegradable polymer networks for use in orthopedic and dental applications
Motala‐Timol et al. Kinetic Study of the Al‐Schiff's Base Initiated Polymerization of ε‐caprolactone and Synthesis of Graft Poly (methylmethacrylate‐g‐caprolactone)
KR101544788B1 (en) Biocompatible polyester block copolymer with side/end functional group and method for manufacturing the same
KR102614952B1 (en) Moldable shape memory polymer-based dental membrane and its manufacturing method
JP2827055B2 (en) Polymer
Peter Injectable, in situ polymerizable, biodegradable scaffolds based on poly (propylene fumarate) for guided bone regeneration
AU2005219452B2 (en) Biocompatible polymer compositions for dual or multistaged curing
Ho Injectable biodegradable poly (ester-co-ether) methacrylate monomers for bone tissue engineering and drug delivery applications
Herath Synthesis and characterization of novel biodegradable crosslinked polyesters
KR20080069799A (en) Method for modifying surface of hydroxyapatite nano-crystal
MXPA97003652A (en) Absalbib polyalykylene diglycollates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 09678816

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2327730

Country of ref document: CA

Ref country code: CA

Ref document number: 2327730

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 543082

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999915349

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999915349

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1999915349

Country of ref document: EP